Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction dated Monday, July 27th. The stock was sold at an average price of $34.95, for a total transaction of $6,990,000.00. Following the completion of the sale, the chief executive officer directly owned 1,613,063 shares of the company’s stock, valued at approximately $56,376,551.85. This trade represents a 11.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Eric Venker also recently made the following trade(s):

• On Wednesday, June 24th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $33.16, for a total transaction of $6,632,000.00.
• On Friday, May 22nd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $30.27, for a total transaction of $6,054,000.00.

Roivant Sciences Trading Down 2.9%

Shares of ROIV traded down $0.97 during mid-day trading on Wednesday, hitting $32.87. The company’s stock had a trading volume of 4,824,003 shares, compared to its average volume of 4,385,496. The company’s 50-day moving average is $32.48 and its 200-day moving average is $28.93. Roivant Sciences Ltd. has a 52-week low of $10.90 and a 52-week high of $37.00. The firm has a market capitalization of $23.64 billion, a price-to-earnings ratio of -54.78 and a beta of 1.11.

Analysts Set New Price Targets

ROIV has been the topic of several recent research reports. Citigroup increased their target price on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, May 21st. HC Wainwright reissued a “buy” rating and issued a $34.00 price target on shares of Roivant Sciences in a research report on Thursday, May 21st. Leerink Partners set a $42.00 price objective on Roivant Sciences in a research report on Thursday, May 21st. Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Finally, TD Cowen lifted their target price on Roivant Sciences from $38.00 to $41.00 and gave the company a “buy” rating in a research note on Thursday, May 21st. Ten research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.59.

Institutional Trading of Roivant Sciences

Several large investors have recently added to or reduced their stakes in the company. Handelsbanken Fonder AB grew its position in Roivant Sciences by 51.4% during the 2nd quarter. Handelsbanken Fonder AB now owns 177,209 shares of the company’s stock worth $6,271,000 after purchasing an additional 60,200 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Roivant Sciences by 18.2% in the second quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock worth $295,965,000 after buying an additional 1,286,464 shares during the last quarter. GAMMA Investing LLC grew its holdings in Roivant Sciences by 17.4% during the second quarter. GAMMA Investing LLC now owns 14,637 shares of the company’s stock worth $518,000 after acquiring an additional 2,172 shares during the period. Versant Capital Management Inc grew its holdings in Roivant Sciences by 13.9% during the second quarter. Versant Capital Management Inc now owns 3,995 shares of the company’s stock worth $141,000 after acquiring an additional 487 shares during the period. Finally, Pacer Advisors Inc. grew its holdings in Roivant Sciences by 37.1% during the first quarter. Pacer Advisors Inc. now owns 96,303 shares of the company’s stock worth $2,668,000 after acquiring an additional 26,044 shares during the period. Hedge funds and other institutional investors own 64.76% of the company’s stock.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.